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ABSTRACT
Objective To examine the effectiveness of the
New Medicine Service (NMS), a national
community pharmacy service to support
medicines-taking in people starting a new
medicine for a long-term condition, compared
with normal practice.
Methods Pragmatic patient-level parallel
randomised controlled trial, in 46 community
pharmacies in England. Patients 1:1 block
randomisation stratified by drug/disease group
within each pharmacy. 504 participants (NMS:
251) aged 14 years and over, identified in the
pharmacy on presentation of a prescription for
asthma/chronic obstructive pulmonary disease,
hypertension, type 2 diabetes or an
anticoagulant/antiplatelet agent. NMS
intervention: One consultation 7–14 days after
presentation of prescription followed by another
14–21 days thereafter to identify problems with
treatment and provide support if needed.
Controls received normal practice. Adherence,
defined as missing no doses without the advice
of a medical professional in the previous 7 days,
was assessed through patient self-report at
10 weeks. Intention-to-treat analysis was
employed, with outcome adjusted for recruiting
pharmacy, NMS disease category, age, sex and
medication count. Cost to the National Health
Service (NHS) was collected.
Results At 10 weeks, 53 patients had withdrawn
and 443 (85%) patients were contacted
successfully by telephone. In the unadjusted
analysis of 378 patients still taking the initial
medicine, 61% (95% CI 54% to 67%) and 71%
(95% CI 64% to 77%) patients were adherent in
the normal practice and NMS arms, respectively
(p=0.04 for difference). In the adjusted intention-
to-treat analysis, the OR for increased adherence
was 1.67 (95% CI 1.06 to 2.62; p=0.027) in
favour of the NMS arm. There was a general trend
to reduced NHS costs, albeit, statistically non-
significant, for the NMS intervention: saving £21
(95% CI −£59 to £100, p=0.128) per patient.
Conclusions The NMS significantly increased
the proportion of patients adhering to their new
medicine by about 10%, compared with normal
practice.
Trial registration numbers ClinicalTrials.gov
trial reference number NCT01635361 (http://
clinicaltrials.gov/ct2/show/NCT01635361).
Current Controlled trials: trial reference number
ISRCTN 23560818 (http://www.controlled-trials.
com/ISRCTN23560818/; DOI 10.1186/
ISRCTN23560818). UK Clinical Research Network
(UKCRN) study 12494 (http://public.ukcrn.org.uk/
Search/StudyDetail.aspx?StudyID=12494).
INTRODUCTION
Adherence to medication is defined as
the extent to which individuals take their
medication as prescribed.1 Suboptimal
medicines adherence has been reported
in many illnesses such as chronic
obstructive pulmonary disease (33%),2
asthma (67%)3 and schizophrenia 52%.4
Adherence reduces with time from initial
prescription. In depression, adherence
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was reported to drop from 95.5% to 52.6% over a
1-month period.5 Low adherence increases risk of
hospitalisations and premature mortality.6–8
Worldwide, medicines non-adherence constitutes 57%
of the estimated US$500 billion wasted from subopti-
mal medicines use.9 The annual economic impact of
non-adherence to five key conditions (asthma, type 2
diabetes, high cholesterol/coronary heart disease,
hypertension and schizophrenia) to the English
National Health Service (NHS England) has been esti-
mated at over £930 million.10 Annual savings of £500
million could be realised if adherence were improved.
Many interventions to improve medicines adherence
are complex, multifaceted and not grounded in theory
about the reasons why people are non-adherent.11
Effective interventions focus on self-management, pro-
moting sustained behaviour change.12 This may involve
more acceptable regimens, removing financial barriers,
changing misguided beliefs about the disease and medi-
cines, empowering self-management, improving patient-
provider relationships and involving the patient’s ‘social
world’. Overemphasis on the educational needs of
patients only is a weakness of many interventions.
When patients receive a new (to them) medicine for
a long-term condition, they often experience problems
which lead to a proportion becoming non-adherent.13
Barber developed an intervention with a theoretical
basis in the self-regulatory model,14 grounded in the
patient’s perspective and designed to elicit patients’
experiences with, and concerns about, their new
medicine. This was used as a starting point for the
pharmacists to meet each individual’s specific needs
with information and advice. This theory-based
pharmacist-led intervention significantly reduced
reported problems and non-adherence in a cost-
effective manner.15 16
The New Medicine Service (NMS) in England is the
first national service designed to improve medicines
adherence17 and is offered by community pharmacists
to people starting a new medicine for asthma/chronic
obstructive pulmonary disease, type 2 diabetes, hyper-
tension or antiplatelet/anticoagulant treatment.18 The
design is based on the initial work described above,
but the original intervention targeted a wider range of
patients whereas the NMS has four specified groups.
The original intervention was delivered via a centra-
lised telephone service, whereas NMS is delivered by
the pharmacist providing the medicine, either
face-to-face or over the telephone. Advanced services
are commissioned nationally via the NHS community
pharmacy contractual framework and can be delivered
following appropriate accreditations. NMS was imple-
mented as an advanced service in October 2011.
Community pharmacies in England have to be accre-
dited to provide NMS and are given guidance on how
to conduct the intervention and follow-up consulta-
tions.18 This guidance provides a topic guide for phar-
macists and an NMS interview schedule. They are
remunerated for each episode of care. Of 11 495 com-
munity pharmacies in England 10 553 (91.2%) had
claimed for at least one NMS episode up to January
2014.19 The aim of this study was to evaluate the
effectiveness of the NMS compared with normal prac-
tice in changing medicines-taking behaviour, using a
robust, pragmatic randomised controlled trial (RCT)
in community pharmacies in England.
METHODS
Study design
The study is reported according to Consolidated
Standards of Reporting Trials (CONSORT) criteria.20
The study was a patient-level multicentre, pragmatic
RCT involving a parallel group design. The study was
overseen by an advisory group. The protocol has been
published.21 22
Study setting
Community pharmacies in East Midlands and South
Yorkshire and Greater London accredited to provide
the NMS were eligible to take part, an area with
approximately 870 pharmacies. Pharmacy selection
took into account pharmacy ownership (independent,
small, medium and large multiples), proximity to
general practice (GP), setting (rural vs urban) and eco-
nomic deprivation.
Study participants
Patients were able to take part in the RCT if they
were eligible for NMS, community-dwelling, aged 14
years or over, able to consent to the NMS and the
study and willing to provide written consent (parental
consent for 14-year-olds and 15 year-olds).
Recruitment
A pragmatic approach was used to include pharmacies
covering the range of characteristics listed above, by
inviting pharmacies from all groups to participate. No
further training on delivering the intervention or
normal practice was provided to prevent alteration of
the pragmatic status of the study. Individual pharma-
cists within the pharmacy had the option to partici-
pate in the study.
Patients were recruited within community pharma-
cies by the study pharmacists (see figure 2).
Consenting to the NMS was a prerequisite for a
patient being invited to the study. It was explained
that if they joined the RCT, they could be randomised
to normal practice, and not receive NMS. Patients
were given as long as they needed to read the study
information and ask questions. The normal 24 h grace
period for consent was not appropriate as the inter-
vention needed to be scheduled while the patient was
in the pharmacy. Therefore, patients received an add-
itional welcome call from the researcher to answer
subsequent questions and patients were also reminded
that they could withdraw.
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Randomisation and blinding
Patients were randomised into one of the two study
arms stratified by drug/disease group within each
pharmacy using Statistical Analysis Software.23 Block
randomisation was used within each pharmacy to
avoid allocation imbalances. Sequentially numbered
tamper-proof opaque sealed envelopes were used to
conceal sequence allocation. Separate randomisation
sequences were produced for patients 16 years and
over and for patients aged 14 years and 15 years,
due to the age-specific motivators for adherence in
this latter group.24 Researchers collecting data were
blinded to study arm except in the case of acciden-
tal disclosure by study participants or when inviting
a participant to the qualitative arm of the study.
The qualitative work is available in the main
report.22
NMS intervention
NMS begins with the patient’s initial presentation
with a prescription for a new medicine in a commu-
nity pharmacy. Patients can be referred to the service
by their prescriber (GP or nurse), can self-refer or the
pharmacist can invite the patient to use the service.
The NMS intervention itself is relatively rapid and
comprises two parts, named ‘intervention’ and
‘follow-up’ by the commissioners. The pharmacist
invites the patient to a one-to-one consultation 7–
14 days later (the ‘intervention’) with a ‘follow-up’
14–21 days after that, meaning the whole episode
should be complete within a maximum of 5 weeks.
These are the points in the service where the pharma-
cist would ask about adherence and experiences with
the medicine. Primary outcomes were collected by
researchers at 10 weeks from initial prescription pres-
entation in both study arms.
The primary aim of the intervention, which can be
face-to-face or telephone-based, (in this study, all
follow-up was via telephone) is the patient-centred
identification of any problems with the treatment
(including adverse drug reactions) and support or
action needed (figure 1). Action may include referring
the patient back their prescriber to review their
medication.
Normal practice
Normal practice was the pharmacist’s usual advice
when presented with a prescription for a new medi-
cine for a long-term condition. No follow-up is
offered to this group of patients. The episode ceases
either until the next prescription is presented or
further assistance is sought by the patient.
Outcomes
Primary outcome
The primary outcome is self-reported adherence at
10 weeks from the initiation of the intervention (see
table 1). Patients were followed up at 10 weeks,
expected to be the minimum time required to demon-
strate any behavioural changes from the
intervention.15
Patients were contacted by telephone and asked
about adherence behaviour using the question:
“People often miss taking doses of their medicines,
for a wide range of reasons. Have you missed any
doses of your new medicine, or changed when you
take it? (Prompt: when did you last miss a dose?)”.25
This is the adherence question asked by pharmacists
during the NMS intervention and follow-up.
The patient was defined as non-adherent if any
doses were missed without the advice of a medical
professional in the previous 7 days.
Figure 1 New Medicine Service intervention.
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The Morisky Eight Item Medication Adherence
Scale (MMAS-8), validated in hypertension, was used
to support the primary outcome measure, and col-
lected via self-completion postal questionnaire
(expected to result in a lower response rate).26
The main intention of the NMS intervention is to
enhance adherence to the newly prescribed medicine.
Situations will inevitably present, such as experiencing
severe side effects, where it would be inappropriate
for a patient to continue taking their prescribed new
medicine. Therefore, the medicine can also be
stopped or changed appropriately by the prescriber,
with or without referral from the pharmacist during
the NMS intervention. Patients’ medicines may also
be stopped or changed appropriately in the normal
practice arm. When a patient’s new medicine was sub-
stituted by another medicine this patient was classed
as having their new medicine changed. On the other
Figure 2 Overview of pharmacy and patient recruitment (CONSORT). ‘Active’ patients indicates how many patients are contributing
data to the study at each time point, by arm. As part of the study pharmacies were asked to provide a 4-weekly return indicating the
number of patients approached, but who declined. Despite significant efforts by the study team throughout, only 25% of these were
returned, meaning an accurate indication of patients approached was not possible. Of the 369 4 week recording periods over the 61
pharmacies, data were received for 94 of these periods. In the remaining periods either pro forma were not returned or returned not
completed. Across the 94 periods, 470 declines were recorded. Declines by pharmacy ranged from 1 to 150. It was therefore not
possible to report the number of patients approached. Patients who did not wish to receive the New Medicine Service (NMS) service
were given a short questionnaire to complete and return to the study team. There were 11 responses from 117 questionnaires issued
with the majority (7/11) stating they did not see the need as their general practice would be reviewing them in due course.
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hand, if a prescriber had directed that the patient stop
their new medicine this was classified as stopped new
medicine. A composite measure of success is the
patient either being adherent to the first medicine, or
it being appropriately stopped or changed. The
outcome is reported as proportion of patients adher-
ent to newly prescribed medicine, or appropriately
stopped or changed by the prescriber (composite out-
come=adherence plus stopped/changed).
Composite outcomes were constructed for the NMS
question and the MMAS-8 by including those patients
adherent to the initial medicine and those whose med-
icines had been stopped or changed appropriately by
the prescriber:
▸ ‘Composite NMS’ (Patients successfully managed com-
posite outcome using NMS question): adherent plus
(stopped or changed appropriately by the prescriber);
▸ ‘Composite MMAS-8’ (Patients successfully managed
composite outcome using MMAS-8): adherent plus
(stopped or changed appropriately by the prescriber).
Other outcomes
Health status, medicines understanding and healthcare
resource use were also recorded.
Costs
Resource use associated with the interventions (time
spent, costs of telephone calls) was recorded for each
patient. Subsequent NHS contact or patient costs
were recorded by the patient in diaries for 10 weeks
after the intervention. Resource use data were
combined with NHS reference costs29 and Personal
Social Services Research Unit costs30 to derive total
costs per patient. Unit costs are summarised in online
supplementary appendix tables 1 and 2. Comparisons
between treatment arms were made using a two-
sample t test on the original data set, or on a boot-
strapped data set, depending on the normality of the
distribution of costs.31
Sample size
Estimation of sample size was based on the effect
observed by the intervention in the original work.15
Prevalence of non-adherence behaviour measured by
the NMS question at 10 weeks follow-up (primary
outcome) was expected to fall from 20% to 10%. A
sample size of 200 patients/arm was required to detect
this change with 80% power, 5% significance level
(two-tailed). Up to 100 patients were expected to be
lost to follow-up, withdraw from the study or change/
stop medication. To maintain study power 250
patients/arm was the planned sample size (table 2).
Starting new medication for one of these long-term
conditions is not that common an event per pharmacy.
Pharmacies initiating at least two NMS consultations/
week were recruited, to provide 52 eligible patients in
6 months. Assuming that 50% of eligible patients con-
sented, approximately 20 pharmacies were needed.
There was lower than predicted NMS uptake within
study pharmacies either because eligible patients were
not presenting, or because the pharmacist could not
identify that the prescription was for a new medica-
tion, due to lack of access to patient medical records.
In 2013 the number of recruiting pharmacies was
expanded to 61, of which 46 ultimately provided
patients. Recruitment was stopped once the required
sample size was reached.
Statistical analysis
Intention-to-treat (ITT) analysis was used.32 33
Adherence rates were analysed using the χ2 test or
Fisher’s exact test. The ITT cohort was defined as all
patients within a randomisation arm with measured
outcomes, or who had withdrawn from the study.
Simple logistic regression analysis assessed
unadjusted effect of NMS on the outcome (Model 1:
‘naïve’ results). Multilevel logistic regression analysis
adjusted effect size for clustering of data and con-
founding by disease, age, sex and medication count
(Model 2). Two levels were defined in the multilevel
analysis: (1) Patient, (2) Pharmacy.
Full application of ITT analysis can only be per-
formed where there is complete outcome data for all
randomised subjects. To include such participants in
an analysis, the outcome data were imputed which
involves making assumptions about the outcomes in
the lost participants.34 35 Generalised estimating equa-
tions36 37 techniques took account of correlated
outcome data. Multiple imputation by chained
Table 1 Summary of outcome measures collected at 10 weeks
Outcome measure Method of recording
Adherence
NMS question Telephone interview*
Adherence
Morisky’s Medication Adherence Scale
8-item version (MMAS-8)26†
Self-completed postal
questionnaire‡
Medicines stopped or changed by the
prescriber
Telephone interview*
Health status
EuroQol-5 Dimension-3 Level Instrument
(EQ-5D-3L)27
Self-completed postal
questionnaire‡
Medicines understanding
Beliefs About Medicines Questionnaire
(BMQ)28
Self-completed postal
questionnaire‡
Healthcare resource use Self-completed diary§
*Participants were asked to specify optimal contact times at registration.
Up to seven attempts were made for each time point if unsuccessful.
†Use of the MMAS is protected by US copyright laws. Permission for use
is required. A license agreement is available from: Donald E Morisky, ScD,
ScM, MSPH, Professor, Department of Community Health Sciences, UCLA
School of Public Health, 650 Charles E. Young Drive South, Los Angeles,
CA 90095–1772.
‡Questionnaires were issued prior to telephone interviews. Return status
was checked during the telephone interview and actioned as necessary.
§Interactions with primary, secondary, social care and allied health
professionals were recorded on an episodic basis. Wasted medicines were
not recorded.
NMS, New Medicine Service.
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Table 2 Patient characteristics
Patient characteristics Normal practice n (%) New Medicine Service n (%)
Total N (%) 253 (100.0) 251 (100.0)
Antiplatelet/anticoagulant (n=43, 8.5%) 19 (7.5) 24 (9.6)
Asthma /COPD (n=117, 23.2%) 58 (22.9) 59 (23.5)
Hypertension (n=249, 49.4%) 128 (50.6) 121 (48.2)
Type 2 diabetes (n=95, 18.8%) 48 (19.0) 47 (18.7)
Female (n=260, 51.6%) 135 (53.4) 125 (49.8)
Male (n=244, 48.4%) 118 (46.6) 126 (50.2)
Age of total cohort (years) (N: Mean (SD)) 253: 59.3 (15.0) 251: 59.5 (15.3)
Age (female) (years) (N: Mean (SD)) 135: 58.7 (15.4) 125: 56.8 (16.0)
Age (male) (years) (N: Mean (SD)) 118: 60.0 (14.6) 126: 62.2 (14.1)
No of NMS eligible new medicine(s) at study
entry (n (%))
Total NMS medicines: 257 Total NMS medicines: 262
1 249 (98.4) 241 (96.0)
2 4 (1.6) 9 (3.6)
3 0 (0.0) 1 (0.4)
Mean (SD) number of other medicines 3.6 (3.4) 3.5 (3.4)
Most commonly prescribed medicines (% medicines prescribed in that disease category)
Antiplatelet/anticoagulant Aspirin 10 (52.6) Aspirin 11 (45.8)
Clopidogrel 7 (36.8) Clopidogrel 9 (37.5)
Dipyridamole 1 (5.3) Dipyridamole 1 (4.2)
Warfarin 1 (5.3) Warfarin 3 (12.5)
Asthma/COPD Salbutamol 11 (18.0) Salbutamol 20 (30.8)
Beclometasone (Clenil) 7 (11.5) Beclometasone (Clenil) 12 (18.5)
Budesonide and formoterol (Symbicort) 7 (11.5) Tiotropium (Spiriva) 10 (15.4)
Tiotropium (Spiriva) 7 (11.5) Fluticasone and salmeterol (Seretide) 6 (9.2)
Formoterol and beclometasone (Fostair) 6 (9.8) Ipratropium 5 (7.7)
Hypertension Amlodipine 40 (30.8) Amlodipine 38 (30.2)
Ramipril 29 (22.3) Ramipril 24 (19.0)
Indapamide 11 (8.5) Losartan 11 (8.7)
Bisoprolol 10 (7.7) Bisoprolol 10 (7.9)
Losartan 10 (7.7) Indapamide 10 (7.9)
Type 2 diabetes Metformin 22 (44.9) Metformin 25 (53.2)
Gliclazide 11 (22.4) Gliclazide 12 (25.5)
Insulin (various) 7 (14.3) Sitagliptin 5 (10.6)
Sitagliptin 5 (10.2) Acarbose 1 (2.1)
Saxagliptin 2 (4.1) Insulin various 2 (4.2)
Economic deprivation based on IMD Score* (Mean (SD))
Pharmacy study sites 30.7 (14.0) 31.1 (13.6)
Study patients 25.0 (15.0) 24.2 (15.3)
Location of pharmacy study site (n (%)
Derbyshire 46 (18.2) 55 (21.9)
South Yorkshire 35 (13.8) 31 (12.4)
Leicestershire 15 (5.9) 10 (4.0)
Nottinghamshire 117 (46.2) 114 (45.4)
Greater London 40 (15.8) 41 (16.3)
Pharmacy ownership† (n (%))
Independent 65 (25.7) 56 (22.3)
Large multiple 63 (24.9) 68 (29.1)
Small multiple 122 (48.2) 123 (49.0)
Supermarket 3 (1.2) 4 (1.6)
*Economic Deprivation Index (Score)—Data from the Office of National Statistics was used to ascertain the deprivation index for each pharmacy using the
postcode as the lookup reference.41 Data were collected for two variables: (1) IMD score and (ii) rank of IMD score. The IMD score is directly proportional
to the level of deprivation (higher IMD score; higher level of deprivation) while the IMD rank is inversely proportional to the level of deprivation (lower IMD
rank; higher level of deprivation). The Office of National Statistics data records the English deprivation scores as ranging from 0.5 to 87.8 and deprivation
rank scores ranging from 1 to 32482.
†Definition of large multiples and supermarkets—the 10 largest pharmacy entities in England, Small multiples—pharmacies with six or more branches and
Independents—pharmacies with one to five 5 branches.42
COPD, chronic obstructive pulmonary disease; IMD, Index of Multiple Deprivation; N, number; NMS, New Medicine Service.
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equations analysis of Model 2 dealt with missing data
(Model 3: sensitivity analysis to check the effects of
the missing data on the outcome).
Predetermined subgroup analyses38 explored
whether effect varied by disease, age, gender, phar-
macy ownership, pharmacy location, number of other
medicines prescribed and deprivation index.
Exploratory analyses of secondary outcome measures
were also carried out.
Study data (disease, age, gender, ethnicity, number
of NMS medicines) were compared with anonymised
national records of completed NMS episodes
from service inception (1 October 2011) to 2
December 2013. (https://www.pharmoutcomes.org/
pharmoutcomes/, Health Information Exchange,
Hampshire).
Statistical analyses were conducted using Statistical
Package for the Social Sciences V.2039 and Stata
V.13.0.40
Pilot study
The study was piloted in four pharmacy sites to
ensure that training, set-up of the pharmacy to oper-
ationalise the study, recruitment methods, study mate-
rials and processes were satisfactory before full
roll-out to all phase 1 pharmacies. Four patients were
recruited as part of the pilot prior to wider roll-out.
RESULTS
The pilot study lasted from July to September 2012,
and no changes were made to the methods prior to
the full study from October 2012 to September 2013.
Between July 2012 and September 2013, 504 patients
were recruited from 46 of the 61 pharmacies (range
1–99 patients).
Researcher blinding was broken 75 times in the
course of the study, (42 in the NMS arm and 33 in
the normal practice arm) accounting for 14.9% of
recruited patients. Of these, 66 instances were pur-
poseful due to checking eligibility for qualitative arm
of the study. The remaining nine were due to either
patient or pharmacist accidentally disclosing their
study arm at phone call.
The two groups were well matched (figure 2) for
patient characteristics (table 2), most commonly pre-
scribed drugs being amlodipine, ramipril and metfor-
min. There was also a similar disease distribution
overall and by gender, age and ethnicity to the
national data set cohort (see online supplementary
appendix table 3).
Effect of NMS on adherence
Results at Week 10 are shown in table 3. By Week 10,
37 and 16 patients had withdrawn from the normal
practice and NMS arms, respectively.
Primary outcome: NMS question
In the unadjusted ITT analysis of 378 patients still
taking the initial medicine, 115/190 (60.5%) and 133/
188 (70.7%) (p=0.037) patients were adherent in the
normal practice and NMS arms, respectively.
Predictions of adherence were calculated on an ITT
basis giving an OR (95% CI) of 1.58 (1.03 to 2.42,
p=0.037), in Model 1. In the adjusted analysis
(Model 2), adherence gave an OR (95% CI) of 1.67
(1.06 to 2.62, p=0.027), in favour of NMS. In the
Table 3 Reported adherence by patients to their new medicine and intention-to-treat analysis of the intervention as a predictor of
adherence at Week 10—frequency counts, unadjusted, adjusted and imputed ORs
N=patients with outcomes
recorded plus withdrawn
patients
Number of adherent
patients/total
responses N (%), p Model* 1 OR (95% CI, p)
Model* 2 (Adjusted)
OR (95% CI, p)
Model* 3 (Imputation)
OR (95% CI, p)
Adherence NMS (N=378, 126 responses missing)
Normal practice 115/190 (60.5) 1.00 1.00 1.00
NMS 133/188 (70.7), 0.037 1.58 (1.03 to 2.42, 0.037) 1.67 (1.06 to 2.62, 0.027) 1.62 (1.04 to 2.53, 0.032)
Composite NMS (N=443, 61 responses missing)† (adherent+stopped+changed)
Normal practice 144/222 (64.9) 1.00 1.00 1.00
NMS 165/221 (74.7), 0.025 1.60 (1.06 to 2.40, 0.025) 1.68 (1.09 to 2.58, 0.018) 1.64 (1.08 to 2.50, 0.021)
Adherence MMAS-8 (N=267, 237 responses missing)
Normal practice 85/143 (59.4) 1.00 1.00 1.00
NMS 89/124 (71.8), 0.035 1.74 (1.04 to 2.90, 0.036) 1.88 (1.06 to 3.34, 0.030) 1.77 (0.96 to 3.28, 0.068)
Composite MMAS-8 (N=321, 183 responses missing)† (adherent+stopped+changed)
Normal practice 108/167 (64.7) 1.00 1.00 1.00
NMS 116/154 (75.3), 0.038 1.67 (1.03 to 2.71, 0.039) 1.78 (1.06 to 3.00, 0.029) 1.81 (1.07 to 3.05, 0.027)
*Model 1: Simple logistic regression model; Model 2 (Adjusted): Multilevel logistic regression model adjusted for recruiting pharmacy, disease, age, sex and
medication count; Model 3 (Imputation): Adjusted logistic regression model incorporating imputation of missing data.
†The difference in numbers of patients with composite and simple adherence outcome is larger for the NMS adherence question, when compared with
MMAS questionnaire (65 and 54, respectively). This is because, at 10 weeks, more patients whose medicine was changed responded to the NMS
adherence question, compared with the MMAS questionnaire (34 and 23, respectively; 11 patients more for the NMS question).
MMAS-8, Morisky’s Medication Adherence Scale 8-item version; N, number; NMS, New Medicine Service.
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full sample (Model 3), the OR (95% CI) was 1.62
(1.04 to 2.53, p=0.032) in favour of NMS.
MMAS-8 and composite outcome
By Week 10, across both groups, there were 37
(8.2%) reports of patients with changed medicines
and 31 (6.9%) reports of patients with stopped medi-
cines. Amlodipine was most often cited as the medi-
cine that was stopped or changed.
When the ITT analysis was carried out using the
composite outcome, or MMAS-8 to measure adher-
ence, similar results to the primary analysis were
obtained.
Exploratory analysis suggested that effect size was
similar across the four therapeutic areas, although
none of the findings were statistically significant (see
online supplementary appendix table 4).
Effect of NMS on other outcomes
No change in beliefs about medicines or health status
was observed (see online supplementary appendix
tables 5 and 6).
Further exploration of contributors to the effective-
ness of the NMS suggested that pharmacy character-
istics (ownership and location) rather than patient
characteristics had an impact (see online supplemen-
tary appendix table 7). The likelihood of being more
adherent following an NMS consultation is almost
double if conducted by a small multiple compared
with an independent (OR 1.00 vs 0.57, p=0.042).
However, as one small multiple recruited 99 patients,
this may have influenced the results unduly. Removal
of this subset of patients did not affect the effect size.
The data for large multiples and supermarkets did not
suggest any difference.
Patients most frequently attributed factors such as
forgetting, experiencing side effects and their beliefs
about their prescribed medicine to their non-adherent
behaviour (see online supplementary appendix
table 8).
Effect of NMS on costs
Mean (median, range) total NHS cost for patients in
normal practice and NMS are £261 (£121, £0–1669),
and £239 (£135, £25–1483), respectively (see online
supplementary appendix table 9). The NMS interven-
tion incurred slightly lower NHS cost, albeit statistic-
ally non-significant, for: £21 (95% CI −£59 to £150,
p=0.1281).
No reports of patient harm due to the intervention
or study participation were reported.
DISCUSSION
The NMS significantly increased the proportion of
patients reporting adherence to their new medicine
by 10.2–70.7%, compared with normal practice,
60.5%. These results were consistent across two
adherence measures and taking account of
confounders and missing data. The cost to the NHS
of paying community pharmacists to deliver NMS
was absorbed by small reductions in other NHS
contact-related costs.
Effect size appeared to be constant across disease
areas. The proportion of non-adherent patients in
each therapeutic group of our sample varies between
disease, which is widely known43 and the proportions
reflect those in the literature.44–50 This consistent
effect supports the theoretical approach of the inter-
vention to allow patient concerns to take priority.
This supports the consideration of offering the service
in diseases currently outside the remit of the current
NMS specification, including mental health. The lack
of consistent direction of effect with increased
age,51 52 sex12 and deprivation status12 24 has been
previously observed.
Pharmacy ownership and location may affect the
effectiveness of NMS but our data are inconclusive
and further work is needed to establish their validity.
Strengths and limitations
This was a pragmatic trial of an existing commis-
sioned service to make sure that results were as gener-
alisable to real-world practice as possible, and was
also a methodologically rigorous trial, such that effect
sizes reported can be considered internally robust.
Sites were closely followed up and supported in
running the trial face-to-face and over the telephone.
Where recruitment was particularly hampered, most
common reasons were NMS conducted in languages
other than English; and pharmacists and patients with
time constraints.
A cluster RCT design was rejected as this would
mean a set of pharmacies would not be able to partici-
pate in NMS and this was unlikely to be acceptable to
pharmacies, which would lose income and competi-
tive advantage. A quasi-experiment (comparing phar-
macies providing NMS with those not providing
NMS) was rejected because of possible differences in
the two populations of pharmacies. The research team
would have had no control over subsequent decisions
of pharmacies to start providing NMS, so would have
potentially lost substantial numbers of the control
group. Patient-level randomisation allowed for control
of pharmacy characteristics. Contamination between
NMS and normal practice patients from the same
pharmacy was very unlikely due to the low frequency
of NMS-eligible patients. The difference between
NMS and normal practice is the presence or absence
of two one-to-one consultations, meaning that the
delivery of one arm is unlikely to be affected by the
delivery of the other arm.
The evaluation was of the implementation of a
commissioned service in the real-world setting so the
research team did not standardise intervention deliv-
ery. To retain the pragmatic design of the study it was
not practicable to quality assure each episode in situ.
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Qualitative work has investigated the variability of
intervention delivery.22
There is no gold standard for measuring patients’
adherence. In this study there were few measurement
options. Direct measures such as measuring plasma
levels are invasive and impractical, and indirect mea-
sures such as ‘pill counts’ are open to bias.
Prescription-filling53 was not an option for routine
monitoring in England due to lack of interoperability
between community pharmacy and GP systems and
patients may use more than one pharmacy. It should
be remembered that the most commonly used object-
ive adherence measure, prescription-filling, has the
limitation that it assumes that a prescription filled is
actually taken by the patient.
Recommended practice is that more than one
adherence measure is employed in a study to provide
some assessment of validity.1 In this study, we chose
two self-report measures. Patient-reported measures
of behaviour and outcome are important.54
Self-report tends to return higher rates of medication
adherence (+15%) than some objective measures,
due to social desirability and memory bias. However,
when patients report they have been non-adherent,
these accounts are generally accurate,55 and patient-
reported adherence correlates with objective clinical
measures.56
It is likely that adherence was overestimated by
patients in both arms of the RCT. Patients in the NMS
arm could have felt under more pressure to report
adherence to their medicine. Reporting bias was mini-
mised through confidential interview,57 normalising
non-adherence by recognising the challenges of taking
regular medications, avoiding leading questions and
asking about missed doses in the week prior to data
collection rather than 1 month or year.58
Patients’ adherence was assessed in the previous
7 days at 10 weeks after the intervention, rather than
as continuum or over the longer term, so it provides a
snapshot of adherence. NMS is designed to improve
adherence early in the therapy, which it has been
demonstrated to achieve. NMS is not intended to be a
one-off intervention that is isolated from care path-
ways, but to be integrated into longer-term medicines
optimisation strategies.
Patient outcomes including hospital admissions and
premature death are improved with increased medi-
cines adherence.59–62 Specific disease pathology and
pharmacology of the medicine moderate the link
between non-adherence and outcomes. For example,
the consequences of non-adherence in epilepsy
become apparent quickly, whereas in hypertension,
non-adherence may not cause morbidity for many
years. Appropriate time intervals after non-adherence
begins need to be incorporated into any appraisals. To
know that patient outcomes will improve as a result
of NMS requires a sufficiently powered study, long
enough to assess impact on patient outcome, with
associated higher research costs, maybe not delivering
timely evidence for policy decision-making.
Comparison with other studies
Community pharmacists can improve adherence to
medication,63 and improve outcomes.64 The effective-
ness in this study is similar to the effectiveness of
more complex adherence interventions, and could be
more effective if recommendations made here are fol-
lowed. It should also be remembered that, given the
high proportion of patients taking medicines, rela-
tively small increases in percentages can affect large
numbers of patients. The intervention developed by
Barber et al, and the basis for design and implementa-
tion of the NMS, produced an absolute 10% increase
in adherence, similar to NMS.15 Interventions to
improve adherence are often multifaceted, without
clear rationale for each part.65 Simpler designs such
as the NMS are needed. Telephone follow-up is a
flexible and relatively low-cost approach. An RCT of
telephone follow-up for patients prescribed a statin
for the first time who hadn’t filled the initial prescrip-
tion showed an increase in adherence from 26% to
42.3% (p=0.001).66 This and our study suggest that
a simple but theory-driven intervention can be
effective.
Implications for clinicians and policy-makers
The NMS is an initiative that encapsulates the prior-
ities and aims of current policies around medicines
optimisation, helping patients and payers.67 However,
the future success of the NMS relies partly on its inte-
gration into primary care provision. Viewing medi-
cines management as an integral part of providing
care for people with long-term conditions provides
support for the continued used of the NMS.68 An
environment enabling a triangular model of relation-
ship and engagement between the patient, GP and
pharmacist is desirable if optimal medicines use is to
be realised. Factors including insufficient integration,
underdeveloped relationships between a patient’s
pharmacist and GP, relatively inaccessible patient
records, poorly devised strategies for targeting services
and the unwillingness by some pharmacists to offer
NMS have hampered the implementation of commu-
nity pharmacy-led clinical services.69 70
Facilitation is needed at local levels, such as tailoring
information technology systems to help foster local
relationships. This requires decision-makers at a
higher level to make funding available. Electronic
integration would allow routine use of prescription-
filling to assess adherence, a proxy measure associated
with limitations, but easier to collect routinely than
self-report if integrated systems exist. Finally, feedback
pathways which incorporate mentoring and opportun-
ities for peer review are recommended for practi-
tioners to enhance their own skills.
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